“Whatever I do, I give it 100 percent,” says this scientist whose work through Roche has impacted millions of patients globally.
After 40 years in the laboratory, Hiro isn’t even close to retiring. “We have so much more to do for patients. There’s no time to waste.”
Hiro, a Senior Scientific Fellow at Roche Diagnostics, has spent much of the past two decades researching and developing diagnostic tests for patients with HER2-positive breast cancer to help determine which patients may benefit from targeted therapy. This aggressive disease is fueled by the amplification of a gene known as HER2, which occurs in as many as 20 percent of the 2.1 million new cases of breast cancer diagnosed globally each year.1,2